Imanova Seeks More Partners For Imaging-Aided Fight Against Neurodegen Disease
Executive Summary
With another fresh injection of funds from the UK Medical Research Council, imaging services provider Imanova is advancing to the next stage of its MIND-MAPS program that aims to identify novel early markers of progression of neurodegenerative diseases, including Alzheimer's and Parkinson's. The data generated from the program could be used to help Imanova's pharma partners develop new therapies to tackle these diseases.